## GRAL: GRAIL, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.8% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($76.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. NWF Advisory Services Inc. Makes New $1.06 Million Investment in GRAIL, Inc. $GRAL**
- Source: MarketBeat | 20251215T130856 | Neutral | Relevance: 100%
- NWF Advisory Services Inc. initiated a new position in GRAIL, Inc. (NASDAQ:GRAL) during the second quarter, acquiring 20,656 shares valued at approximately $1.06 million, while other institutional investors also adjusted their holdings. The article highlights recent insider selling activity by GRAIL's CEO and President, totaling about $7.38 million over 90 days. Analyst ratings for GRAIL are mixed but show an upward trend, with a current consensus "Hold" rating and a target price of $97.50, following a recent EPS beat despite negative margins.

**2. 64,560 Shares in GRAIL, Inc. $GRAL Bought by Caxton Associates LLP**
- Source: MarketBeat | 20251215T090856 | Somewhat-Bearish | Relevance: 100%
- Caxton Associates LLP has acquired a new stake of 64,560 shares in GRAIL, Inc. (NASDAQ:GRAL) worth approximately $3.32 million during the second quarter. Despite this purchase and several analyst upgrades with price targets up to $110, GRAIL has seen significant insider selling from its CEO and President, totaling about $7.38 million in the past three months. The stock is currently trading down 4.5% with a market capitalization of $3.54 billion, still reporting negative EPS and P/E ratios despite beating quarterly revenue estimates.

**3. Trading the Move, Not the Narrative: (GRAL) Edition**
- Source: Stock Traders Daily | 20251214T152400 | Somewhat-Bearish | Relevance: 100%
- This article analyzes Grail Inc Com (NASDAQ: GRAL), indicating a mid-channel oscillation pattern and divergent sentiment across different time horizons. It highlights an exceptional short setup with a significant risk-reward ratio and details distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for various risk profiles. The analysis is supported by AI-generated signals and multi-timeframe signal analysis, providing entry/exit zones and risk parameters.

**4. BBR Partners LLC Sells 35,000 Shares of GRAIL, Inc. $GRAL**
- Source: MarketBeat | 20251213T100833 | Somewhat-Bearish | Relevance: 100%
- BBR Partners LLC significantly reduced its stake in GRAIL, Inc. (NASDAQ:GRAL) by 77.8%, selling 35,000 shares and ending Q2 with 10,001 shares valued at $514,000. Insider selling has also been substantial, with CEO Robert Ragusa and President Joshua Ofman selling a combined 13,353 shares, contributing to a total of 113,295 insider shares worth $7.38 million sold in the past 90 days. Despite mixed analyst ratings, with some upgrades and higher price targets, the stock holds a consensus "Hold" rating with an average price target of $97.50.

**5. GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: PR Newswire | 20251215T210856 | Neutral | Relevance: 100%
- GRAIL, Inc. announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 12 at 7:30 a.m. PT. A webcast of the presentation will be available on the investor relations section of GRAIL's website. GRAIL's mission is to detect cancer early using next-generation sequencing and machine learning to identify multiple deadly cancer types in their earlier stages.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $110 | $85 | +29% |
| 2025-11-17 | Canaccord Genui | $105 | $85 | +24% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Equal-Weight |
| 2025-11-17 | Canaccord Genui | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 4 |

**Top Holders:**
- Blackrock Inc.: 6.3% (+0.7%)
- Primecap Management : 5.2% (-1.6%)
- CRCM LP: 4.7% (-49.5%)
- Vanguard Group Inc: 4.7% (-4.5%)
- Baker Bros. Advisors: 4.2% (0.0%)

### Key Risks

1. High beta (3.63) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. High short interest (15.6%, 4.5 days to cover): squeeze risk or crowded bearish bet.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Balance sheet: strong liquidity (7.6x), low leverage (D/E 0.16). Analyst sentiment positive (2 raises, avg +26%). Institutional flow bullish (4 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.5B |
| Beta | 1.00 |
| 52W Range | $16.10 - $115.76 |
| Short Interest | 15.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -6.0% to -4.8% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 7.8pp (needs >3.0% for momentum thesis). Underperforming sector by 6.3pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.84x) but short-term weakness (below SMA20). MACD histogram bearish (-2.09), momentum weakening. RSI neutral at 48. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.83% (CS: 8) | Weak |
| RSI_14 | 47.7 | Neutral |
| MACD Histogram | -2.09 | Bearish |
| vs SMA20 | 0.936x | Below |
| vs SMA50 | 1.045x | Above |
| vs SMA200 | 1.841x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $91.04
- **Stop Loss:** $76.38 (16.1% risk)
- **Target:** $105.70 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 81
- **Position Value:** $7,374.24
- **Portfolio %:** 7.37%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-19 (Est: $-2.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-3.27 | $-2.46 | +24.7% |
| 2025Q2 | $-3.56 | $-3.18 | +10.8% |
| 2025Q1 | $-3.80 | $-3.10 | +18.5% |
| 2024Q4 | $-4.97 | $-2.89 | +41.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*